Literature DB >> 9459566

Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells.

K N Klotz1, J Hessling, J Hegler, C Owman, B Kull, B B Fredholm, M J Lohse.   

Abstract

Four adenosine receptor subtypes of the family of G protein-coupled receptors, designated A1, A2A, A2B and A3 are currently known. In this study all human subtypes were stably transfected into Chinese hamster ovary (CHO) cells in order to be able to study their pharmacological profile in an identical cellular background utilizing radioligand binding studies (A1, A2A, A3) or adenylyl cyclase activity assays (A2B). The A1 subtype showed the typical pharmacological profile with 2-chloro-N6-cyclopentyladenosine (CCPA) as the agonist with the highest affinity and a marked stereoselectivity for the N6-phenylisopropyladenosine (PIA) diastereomers. In competition with antagonist radioligand biphasic curves were observed for agonists. In the presence of GTP all receptors were converted to a single low affinity state indicating functional coupling to endogenous G proteins. For A2A adenosine receptors CGS 21680 (2-[p-(2-carboxyethyl)phenylethylamino]-5'-N-ethylcarboxamidoadeno sine) and N-ethylcarboxamidoadenosine (NECA) were found to be the most potent agonists followed by R- and S-PIA with minor stereoselectivity. The relative potencies of agonists for the A2B adenosine receptor could only be tested by measurement of receptor-stimulated adenylyl cyclase activity. NECA was the most potent agonist with an EC50-value of 2.3 microM whereas all other compounds tested were active at concentrations in the high micromolar range. Inhibition of NECA-stimulated adenylyl cyclase identified xanthine amino congener (XAC; 8-[4-[[[[(2-aminoethyl)amino]-carbonyl]methyl]oxy]phenyl]-1,3-dipropylxa nthine) as the most potent antagonist at this receptor subtype. The A3 receptor was characterized utilizing the nonselective agonist [3H]NECA. The N6-benzyl substituted derivatives of adenosine-5'-N-methyluronamide (MECA) turned out to be the most potent agonists. The notion of xanthine-insensitivity of the A3 receptor should be dropped at least for the human receptor as xanthines with submicromolar affinity were found. Overall, the pharmacological characteristics of the human receptors are similar to other species with some species-specific characteristics. In this study we present for the first time the comparative pharmacology of all known human adenosine receptor subtypes. The CHO cells with stably transfected adenosine receptors provide an identical cellular background for such a pharmacological characterization. These cells are valuable systems for further characterization of specific receptor subtypes and for the development of new ligands.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9459566     DOI: 10.1007/pl00005131

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  110 in total

1.  Signaling by extracellular nucleotides and nucleosides.

Authors:  P Illes; K N Klotz; M J Lohse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

2.  Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells.

Authors:  B C Suh; T D Kim; J U Lee; J K Seong; K T Kim
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

3.  A(1)-, A(2A)- and A(3)-subtype adenosine receptors modulate intraocular pressure in the mouse.

Authors:  M Y Avila; R A Stone; M M Civan
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

4.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

5.  ATP-sensitive K(+) channels regulate the concentrative adenosine transporter CNT2 following activation by A(1) adenosine receptors.

Authors:  Sylvie Duflot; Bárbara Riera; Sonia Fernández-Veledo; Vicent Casadó; Robert I Norman; F Javier Casado; Carme Lluís; Rafael Franco; Marçal Pastor-Anglada
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

6.  Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice.

Authors:  Ilia Korboukh; Emily A Hull-Ryde; Joseph E Rittiner; Amarjit S Randhawa; Jennifer Coleman; Brendan J Fitzpatrick; Vincent Setola; William P Janzen; Stephen V Frye; Mark J Zylka; Jian Jin
Journal:  J Med Chem       Date:  2012-07-16       Impact factor: 7.446

Review 7.  Xanthines as adenosine receptor antagonists.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2011

8.  Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay.

Authors:  Miklós Kecskés; T Santhosh Kumar; Lena Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-05-11       Impact factor: 5.858

9.  Exploring distal regions of the A3 adenosine receptor binding site: sterically constrained N6-(2-phenylethyl)adenosine derivatives as potent ligands.

Authors:  Susanna Tchilibon; Soo-Kyung Kim; Zhan-Guo Gao; Brian A Harris; Joshua B Blaustein; Ariel S Gross; Heng T Duong; Neli Melman; Kenneth A Jacobson
Journal:  Bioorg Med Chem       Date:  2004-05-01       Impact factor: 3.641

10.  Human breast cancer cell line MDA-MB-231 expresses endogenous A2B adenosine receptors mediating a Ca2+ signal.

Authors:  Mojtaba Panjehpour; Marián Castro; Karl-Norbert Klotz
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.